chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 26Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 51 years for COVID-19 immunization; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for COVID-19 immunization. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Negative, notes: became symptomatic after having previously testing negative post-Paxlovid; (unspecified date) Positive, notes: Treatment of COVID-19; (18May2022) Positive, notes: Relapse 10 days after Paxlovid, tested positive. Therapeutic measures were taken as a result of drug ineffective, COVID-19. Patient took Paxlovid on 08May2022 and stopped on 12May2022 for the treatment of COVID-19.   Clinical course: There were no known allergies. The patient had no other medications in 2 weeks.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Mild, Systemic: Stiff Neck-Medium
Stroke, hospitalized 5 days, sent to skilled care (nursing home), death 2 weeks after stroke
Information has been received from a physician concerning a 31 year old male with no medical history and no allergies who on 04/25/03 was vaccinated SC with a dose of varicella virus vaccine live. There was no concomitant medication. On approximately 05/05/03, 10-14 days after vaccination, the pt developed a mild varicella-form rash. No other symptomology was reported. No diagnostic studies were performed. Unspecified medical attention was sought and it was reported that no treatment was required. Subsequently, the pt recovered. No product quality complaint was involved. Additional information has been requested.
A consumer report has been received. The report concerns a 39 year 3 weeks 5 days old male patient. Patient was a medimmune employee. Patient reported he got vaccination FLUMIST (intranasal) in Nov-2015 because they were giving out free FLUMIST at work. 09-Apr-2016 patient was diagnosed with Influenza strain B (Preferred Term: Influenza). Patient received vaccination through the Health and Wellness Center. FLUMIST QUADRIVALENT was continued. The outcome of the event of influenza strain B was unknown. The report was considered to be non-serious by company physician.
This 15 yo had a near syncope episode, falling to floor approximately 5 to 10 minutes after 4 vaccines were given. No head injury. No loss of consciousness (BP at time low 96/62, HR 112). (Before vaccines given 4-23-10 BP 110/60, P 82 all WNL).
crohn's flare up and was out of work for a month; Joint pain; This is a spontaneous report from a contactable consumer (patient). A 54-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Batch/Lot Number: EP6955; Expiration Date: 30Jun2021), via an unspecified route of administration on 24Mar2021 (at the age of 54-years-old) as dose 1, single for COVID-19 immunization. The patient medical history included crohn's disease (diagnosed over 20 years ago), acid reflux (esophageal). The patient concomitant medications included mesalazine (LIALDA) (MANUFACTURER UNKNOWN), via an unspecified route of administration at unspecified date at 1.2 g, daily (per day) for crohn's disease; omeprazole (PRILOSEC) (MANUFACTURER UNKNOWN), via an unspecified route of administration at unspecified date at 20 mg, once a day for acid reflux (esophageal). On an unspecified date, the patient experienced crohn's flare up and was out of work for a month, joint pain. The patient is calling about the covid vaccine. The patient was weaning off some of the medications with the doctor permission, Lialda. The patient can't remember when symptoms started to return but it closely corresponded with when the patient was vaccinated. The patient had a Crohn's flare up and was out of work for a month. Lialda lot, NDC, and expiration date not probed as it is not a Pfizer product. The patient has been seeing his GI doctor for the treatment of his flare up. The patient is getting close to getting his Crohn's back into remission, his blood work yesterday showed that it is almost there. Event: The patient is unsure when the symptoms started coming on. The joint pain started right around the first dose and then he got the second shot in the middle of April. The symptoms were getting increasingly worse at the end of May and then the middle of May is when they started changing up the mediations. The patient also had blood work on 27May2021. The clinical outcome of the joint pain was unknown and crohn's flare up and was out of work for a month was recovering.
colitis(5/8) and esophageal dilation (5/18) who presents with fever, chills, esophageal/epigastric pain and dysphagia as well as incidental finding of cecal bascule
9-10 days after vaccination I started having symptoms of allergic reaction. I had hives all over my body and swelling in my face.   It was bad enough that I went to the ER the following day. They gave me prednisone and Benadryl, which helped my symptoms.   Symptoms have gotten less severe but I am still needing to take Allegra and famatidone to keep symptoms at bay.  More than a month later I am still getting rashes. I can?t confirm that it was the vaccine for sure, but I have found many similar accounts on the Internet of others having very similar reactions after getting a moderna booster.
Patient received their first dose of Moderna vaccine today. After about 7-8 minutes, the patient said she was starting to feel dizzy. The pharmacist escorted her into the immunization booth to sit and monitor her. She attempted to take the patient's blood pressure but the machine errored out on the first attempt. The patient was sweating so the pharmacist applied a cold compress to the patients neck and wrists. The patient said she was possibly seeing a couple of spots, but said that this was a common reaction when she is nervous. The pharmacist took the patient's blood pressure again and got a reading of 92/57. The patient stated that her blood pressure usually runs low, though. About 30 minutes after the vaccine the patient stated that her symptoms had all resolved. She was no longer dizzy, no visual disturbances, and no longer sweaty.  Her husband drove her home shortly after that when the patient felt she was better.
Headache, Myalgia, Arthralgia, Fever, Chills, Dyspnea, Fatigue, Injection site pain Narrative:
Joint pain; Chills; Shaking; Nausea; Fatigue; Foggy thinking; Diarrhea/loose stools; Weakness; Injection site pain; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 16Apr2021 at 10:15 at the age of 52-years-old as a single dose for COVID-19 immunisation. Medical history included COVID-19 prior to the vaccination, the patient was diagnosed with COVID-19 and allergy to night shades. Concomitant medications included PROTEASE and TILACTASE for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8728) via an unspecified route of administration in the left arm on an 26Mar2021 at 10:15 at the age of 52-years-old as a single dose for COVID-19 immunisation. On 16Apr2021 at 18:00, the patient experienced joint pain, chills, shaking, nausea, fatigue, foggy thinking, diarrhea, loose stools, weakness, and injection site pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events joint pain, chills, shaking, nausea, fatigue, foggy thinking, diarrhea, loose stools, weakness, and injection site pain was resolved with sequelae on an unknown date in Apr2021.                 No follow-up attempts are needed. No further information is expected.
Sever joint pain of the knees, hips, elbows and wrists.; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: fa7484) via an unspecified route of administration in the left arm on 26Jul2021 at 01:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food, or other products. The patient did not receive any medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Jul2021 at 03:30 the patient experienced severe joint pain of the knees, hips, elbows and wrists. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events severe joint pain of the knees, hips, elbows and wrists was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
pt recv vax 29JUN95 & 1JUL95 pt exp lt parotitis & lt facial droop;impression was lt bells palsy;pt recovered 21JUL95
Vaccine given to patient and had a reaction to the vaccine. Patient appeared to have a vaso-vagal reaction   color drained from his face and broke out in a sweat and then became unresponsive, then woke up. Moved to stretcher and vital signs monitored, heart rate to 40,appeared to have a seizure and post ictal. Mom present, instructed to call pediatrician and ask about second dose administration. Patient given OJ and banana, monitored for over an hour, color and VS improved, discharged with Mom.
patient received pfizer covid19 vaccination on L deltoid. Immediately after vaccination patient stated "I am feeling like faint." Patient clenched her hands and neck became rigid and lops noted pale. Reporter called for help and health clinician was present and assisted patient to lay down to the ground in a supine position and elevated both lower extremities on a chair. Patient was unresponsive for 20 seconds. After 20 seconds, patient stated "I am coming back." Patient was since A+Ox3 and following directions well. However, patient reported feeling nauseous and slightly tingly in the fingers. After a few minutes, the tingling sensation subsided, but the nauseous persisted. Vital signs were WNL throughout. After 20 minutes, patient reported no signs of improvement. EMS was initiated.
This case was reported by a nurse and described a 57 year old female subject who did not respond to immunization to the Engerix-B immunization series. Past medical history, concurrent conditions and concurrent medications were unknown. On 06 April 2005, the subject received the third dose of Engerix-B. The other two doses were given on 28 October 2004 and 28 September 2004. On 06 May 2006, one month after vaccination with Engerix-B, it was reported that the subject had a negative hepatitis B antibody titer. Further information was not reported.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old male patient received BNT162b2 (BNT162B2), on 06Mar2021 as dose 1, single (Lot number: en6199), on 27Mar2021 as dose 2, single (Lot number: er2613), on 09Oct2021 as dose 3 (booster), single (Lot number: ff2950) and on 23Apr2022 as dose 4 (booster), single (Lot number: fj4989) at the age of 64 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "copd" (unspecified if ongoing); "heart issues" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "asthma" (unspecified if ongoing); "general allergies" (unspecified if ongoing); "Prediabetes" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Sep2022, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19 included Paxlovid.
Bruising and petechia on limbs, torso and oropharynx. Platelet count of 1. Hospitalized x2 in 3 wks. Received IVIG x2 to treat ITP. Bruising began 2 wks after vaccines.
Every joint in my body is painful; Need a nap in order to function; Mood changes (very sad and angry); Mood changes ( very sad and angry); Mood changes ( very sad and angry); This is a spontaneous report from a contactable consumer. This 43-year-old female consumer (patient) reported that she received bnt162b2 (BNT162B2, Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Right on 08Mar2021 12:45 (Batch/Lot Number: En6203) as SINGLE DOSE for covid-19 immunisation. Medical history included asthma, depression, food allergy from an unknown date and unknown if ongoing. Concomitant medications included montelukast (MONTELUKAST) taken for an unspecified indication, start and stop date were not reported; diphenhydramine hydrochloride (BENADRYL) taken for an unspecified indication, start and stop date were not reported. The patient previously took septocaine and experienced drug hypersensitivity. On 10Mar2021 the patient experienced every joint in my body is painful, need a nap in order to function, mood changes (very sad and angry). The action taken in response to the events for bnt162b2 was not applicable. The outcome of the events was not recovered.  No follow-up attempts are possible. No further information is expected.
Moderate Nausea, chills, fever x 2 days, extreme fatigue x 4 days, moderate ongoing injection site pain.  Headache.
Patient first experiencing angioedema on 8/28- prompting ED visit and treatment (EpiPen, prednisone, diphenhydramine, famotidine) but was later sent home. Unable to determine cause- of note, patient started on Cipro 3 days prior. Returned to ED on 8/30 and was then admitted to ICU for angioedema and had diffuse urticarial rash. Given steroids, benadryl, famotidine, and epinephrine. Required epinephrine drip when admitted to MICU. Discharged 8/31. Had follow up appointments with allergist for allergy testing. Suspected tehre is a remote possibility her Moderna vaccination induced a sensitivity to PEG which was triggered by Miralax powder administered on the job. Therefore to be cautious, she is to avoid handling PEG powder or suspension
SWOLLEN-WIDTH OF A GOLFBALL SLIGHT PROTRUDING; LIGHT RED AREA AROUND THE INJECTION AREA; ENTIRE BODY ACHE/PAIN; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805020, and expiry: 25-MAY-2021) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021, the subject experienced entire body ache/pain. On 10-APR-2021, the subject experienced swollen-width of a golfball slight protruding. On 10-APR-2021, the subject experienced light red area around the injection area. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from entire body ache/pain on 09-APR-2021, and had not recovered from swollen-width of a golfball slight protruding, and light red area around the injection area. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure as case assessed as non-serious
This spontaneous report as received from a physician refers to a patient of unknown age and gender. Medical history and concurrent conditions were not reported. On 05-APR-2015, the patient was vaccinated with an expired dose of ZOSTAVAX lot # J014566, expiration date 18-FEB-2015, 0.65 ml, subcutaneous. No co-suspect and concomitant therapies were reported. No symptoms reported. Additional information has been requested.
Patient felt lightheaded immediately after vaccines received.  Color of skin was pale.  Patient was accompanied by mother and they waited in the waiting room for a few minutes before leaving.  Mother reports son said "I don't feel right and was nauseous" returned to school and reported a headache and some dizziness. Vomited once before 6 pm, but still went to work.  He worked a 3 hour shift and vomited a couple of times while at work.  Came home and skipped supper and went to bed.  Mom states he vomited off and on throughout the night.  Stayed home from school the following day.  Redness and a bump under the skin on right arm.  No more vomiting at this time.
The shot was administered by a young woman at pharmacy, who I later learned was an intern. She injected the shot less than two fingers down from my shoulder bone, much higher than I have ever had an injection given before.  I immediately felt intense pain, and the intern had trouble pushing the syringe down fully.  She said ?I need help!?, and her male manager ran over, and quickly jabbed the syringe further into my arm, and pressed extremely hard down on the syringe, forcing the remaining contents into my arm. I immediately felt a shooting, searing pain down my entire arm, into my wrist, and  my arm went numb, felt heavy, and tingly by my hand.  The manager pulled the needle out of my arm, and said ?you must have hit bone, the needle is bent?.  I then felt extremely nauseous and woozy, and my vision started going in and out.  I fanned myself and after about five minutes my vision stabilized, and I felt less nauseous.  It is now 9 hours later and I have intense shoulder and neck pain, and limited range of motion of my shoulder.
Inadvertently administered the Pfizer vaccine after being in refrigerator for 33 days. Manufacturers label suggests that the product should be in the refrigerator for no longer than a month.
Very hurtful arm, barely moving; Throwing up; Teeth were chattering/Chills; Feeling very weak; This is a spontaneous report from a contactable consumer or other non-healthcare professional. This case is for reporter's husband. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number was not reported), dose 2 via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient previously received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunization. On an unspecified date, the patient experienced very hurtful arm, barely moving, throwing up, chills/teeth were chattering and feeling very weak. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021758715 Same reporter/drug/AE, different patient;US-PFIZER INC-2021758769 Same reporter/drug/AE, different patient
shingles; Information has been received from a lawyer regarding a case in litigation concerning a female patient (pt) of unknown age. The pt's medical history, concurrent conditions and concomitant medications were not provided. On or about 17-DEC-2012, the pt was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot#, expiration date were unknown) by a pharmacist in a pharmacy for the long-term prevention of shingles and/or zoster-related conditions. Subsequent to pt's zoster vaccine live (ZOSTAVAX) inoculation, pt was treated by a certified physician assistant for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles was unknown and the causal relationship between shingles and zoster vaccine live (ZOSTAVAX) was considered related.
Injection site pain, malaise, headache, chills, fatigue, low grade fever, swollen  lymph nodes, skin tingling, joint pains, muscle aches
vaccinated with the 3 doses of the Pfizer COVID-19 vaccine, tested positive for Covid/sore throat; vaccinated with the 3 doses of the Pfizer COVID-19 vaccine, tested positive for Covid/sore throat; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient received BNT162b2 (BNT162B2), on 04Mar2021 as dose 1, single (Lot number: EN6199), in arm, on 25Mar2021 as dose 2, single (Lot number: EN6207), in arm and on 17Nov2021 as dose 3 (booster), single (Lot number: FH8030) at the age of 62 years, in arm for covid-19 immunisation. The patient's relevant medical history included: "Hypothyroidism" (unspecified if ongoing), notes: A long time ago, maybe 10-year- ago. Concomitant medication(s) included: SYNTHROID oral taken for hypothyroidism. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 25Jul2022, outcome "not recovered" and all described as "vaccinated with the 3 doses of the Pfizer COVID-19 vaccine, tested positive for Covid/sore throat". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jul2022) Negative; (25Jul2022) Positive; (30Jul2022) a weak positive; (01Aug2022) Negative; (05Aug2022) slightly positive; (05Aug2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: Vaccinated with the 3 doses of the Pfizer COVID-19 vaccine, tested positive for COVID. 1st dose: NDC number, lot number, expiration date: Says EN6199 on the vaccination card. Unknown what that number is; 2nd dose: NDC number, lot number, expiration date: Says EN6207 on the vaccination card. Unknown what that number is; 3rd dose: NDC number, lot number, expiration date: Says FH8030 on the vaccination card.  No follow-up attempts are possible, no further information is expected.